Kane Biotech to Host Commercial Update Webcast on September 16

Article content

Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane’s commercial progress, clinical relevance and operational priorities

Article content

WINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will host a virtual Commercial Update on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time.
                  
The one-hour webcast will provide shareholders, prospective investors and other stakeholders with an update on Kane’s focus on building a clinically credible and commercially disciplined wound-care business, including the Company’s strategy to convert revyve^® into meaningful, recurring revenue through sustained clinical adoption, productive commercial channels and repeatable product sales.

Article content

Article content

Article content

The details of the Webcast are as follows:

Article content

Article content

Date: Wednesday, September 16, 2026
Time: 11:00 a.m. Eastern Time
Duration: Approximately 60 minutes, including a question-and-answer session
Format: Virtual presentation followed by a question-and-answer session
Registration:
Link to Registration Site

Article content

Investors, shareholders and other stakeholders are encouraged to register in advance to participate in the live webcast and Q&A session. A replay of the webcast will be made available at www.kanebiotech.com following the event.

Article content

Article content

Article content

U.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray

Article content

Mr. Philip Renaud, Chair of Kane’s Board of Directors, will participate in the presentation.

Article content

Dr. John C. Lantis, Site Chief of Surgery at Mount Sinai West Hospital and Professor of Surgery at the Icahn School of Medicine at Mount Sinai, will also participate in the presentation. Dr. Lantis is an experienced vascular surgeon and wound-care investigator who has served as principal investigator on more than 70 multicentre and single-centre chronic-wound and vascular-surgery trials. His presentation will provide an expert clinical perspective on chronic wounds, wound biofilms and the practical requirements for bringing new wound-care technologies into clinical use, including his experience with revyve Antimicrobial Wound Spray in venous leg ulcers.

Article content

Article content

Dr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, will present an operational and commercial update. The presentation will address the work undertaken to strengthen Kane’s commercial foundation, advance its clinical evidence strategy, expand routes to market and focus the Company on converting commercial access into repeatable product adoption and revenue.

Article content

“Over the past year, Kane has changed how it approaches governance, evidence generation and commercialization,” said Philip Renaud, Chair of the Board. “This webcast gives us an opportunity to speak directly to shareholders and other stakeholders about that work, put the Company’s progress into clear clinical and commercial context, and outline the execution priorities that will guide Kane’s next phase.”

Article content

Kane’s revyve portfolio currently includes U.S. FDA 510(k) cleared revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser. The wound gel and wound gel spray are also approved by Health Canada. Kane is ISO 13485:2016 certified under the Medical Device Single Audit Program.